Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
237.1 CHF | +0.98% | +5.33% | -3.03% |
May. 17 | Health Care Up on Rotation to Sector From Rate-Sensitive Groups -- Health Care Roundup | DJ |
May. 17 | ROCHE HOLDINGS AG : UBS sticks Neutral | ZD |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's enterprise value to sales, at 3.38 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.03% | 211B | A+ | ||
+32.09% | 693B | C+ | ||
+29.39% | 584B | B | ||
-1.34% | 372B | C+ | ||
+20.34% | 332B | B- | ||
+7.39% | 294B | C+ | ||
+14.25% | 239B | B+ | ||
+10.02% | 210B | B- | ||
+8.49% | 168B | C+ | ||
-0.52% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROG Stock
- Ratings Roche Holding AG